Gestational Trophoblastic Neoplasia Clinical Trial
Official title:
Phase 2 Single Agent Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia (GTN)
The purpose of this study is to see if Dostarlimab is an effective treatment for Gestational Trophoblastic Neoplasia (GTN).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04562558 -
Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
|
N/A | |
Not yet recruiting |
NCT06020755 -
Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7
|
Phase 2 | |
Recruiting |
NCT06028672 -
Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6
|
N/A | |
Terminated |
NCT02664961 -
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
|
Phase 2 | |
Recruiting |
NCT03703271 -
Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
|
Phase 3 | |
Not yet recruiting |
NCT04303884 -
Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)
|
Phase 2 | |
Recruiting |
NCT05139095 -
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
|
Phase 2 | |
Recruiting |
NCT05635344 -
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
|
Phase 2 | |
Recruiting |
NCT04756713 -
Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia
|
Phase 3 | |
Recruiting |
NCT03785574 -
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
|
N/A | |
Active, not recruiting |
NCT01823315 -
Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia
|
Phase 3 | |
Not yet recruiting |
NCT06169644 -
The Psychological Impact of GTN on Women Who Have Completed Chemotherapy Treatment
|
||
Recruiting |
NCT04812002 -
Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
|
Phase 2 |